Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg,
60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with
Amgen Inc, Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of
Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately
US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.
Cinacalcet Hydrochloride tablets are indicated for the treatment of:
Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on
dialysis
Hypercalcemia in adult patients with parathyroid carcinoma
Severe hypercalcemia in adult patients with primary HPT who are unable to undergo
parathyroidectomy
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
